You searched for Value, Affordability, and Decision Making - Page 2 of 3

We found for

Insight
March 2022

NICE’s severity modifier: a step in the right direction, but still a long way to go

Insight
March 2022

The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?

Insight
March 2022

Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?

Insight
March 2022

No Smoking Day 2022: Reflecting on OHE Projections from 1994

Insight
February 2022

Rare Disease Day 2022

Insight
February 2022

New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Insight
December 2021

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

News
November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Insight
July 2021

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?

Insight
June 2021

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Insight
April 2021

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Insight
April 2021

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Insight
April 2021

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Insight
March 2021

Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System

Latest Research & Publications

All Publications

We found for

Filter results by

NICE’s severity modifier: a step in the right direction, but still a long way to go

The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?

Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?

No Smoking Day 2022: Reflecting on OHE Projections from 1994

Rare Disease Day 2022

New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System